Genmab — Maj 2017
-
Så må I tænke jer til hvederne:-)
-
positive results for durvalumab in non-small cell lung cancer , AstraZeneca +5%
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-12052017.html -
-
I NSCLC er dara i et kombiforsøg med atezolizumab, som også er en PD-L1-blokker. https://www.clinicaltrials.gov/ct2/show/NCT03023423?term=luc2001&rank=3
-
-
Dara + Opdivo testes også i NSCLC. se side 9 i vedlagte http://files.shareholder.com/downloads/AMDA-KPIBN/138540251x7895654x942273/927E2A2C-FE48-411B-8753-CB30A0B296E1/Q1_2017_Interim_Report_final.pdf
-
Hej alle. Nu hvor markedet er lukket, kan vi jo bruge tiden på noget lidt andet
Jeg skal skrive en skoleopgave om en valgfri virksomhed. Det blev selvfølgelig Genmab.. Kan i give mig navne og tal på Genmabs største aktionærer? På forhånd tak 
-
Plesner: Vi forstår ikke, hvorfor der ikke er flere bivirkninger ved dara http://www.vjhemonc.com/video/quvg59hezii-what-are-the-practical-considerations-for-monoclonal-antibody-infusion/?platform=hootsuite
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind